SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI)

Diabetes Res Clin Pract. 2022 Nov:193:110141. doi: 10.1016/j.diabres.2022.110141. Epub 2022 Nov 4.

Abstract

Aims/hypothesis: Established dysglycaemia (impaired glucose tolerance [IGT] or type 2 diabetes [T2DM]) is a risk factor for further cardiovascular events in patients with coronary artery disease. Sodium-glucose cotransporter 2 inhibitors reduce this risk. The aim of the present investigation was to test the hypothesis that empagliflozin exerts beneficial effects on myocardial function in patients with a recent acute coronary syndrome and newly detected dysglycaemia.

Methods: Forty-two patients (mean age 67.5 years, 81 % male) with recent myocardial infarction (n = 36) or unstable angina (n = 6) and newly detected IGT (n = 27) or T2DM (n = 15) were randomised to 25 mg of empagliflozin daily (n = 20) or placebo (n = 22) on top of ongoing therapy. They were investigated with oral glucose tolerance tests, stress-perfusion cardiac magnetic resonance imaging (CMR) and echocardiography at three occasions: before randomisation, after seven months on study drug and three months following cessation of such drug. Primary outcome was a change in left ventricular (LV) end-diastolic volume (LVEDV) and secondary outcomes were a change in a) systolic and diastolic LV function; b) coronary flow reserve; c) myocardial extracellular volume (ECV) in non-infarcted myocardium; d) aortic pulse wave velocity.

Results: Empagliflozin induced a significant decrease in fasting and post load glucose (p < 0.05) and body weight (p < 0.01). Empagliflozin did not influence LVEDV, LV systolic or mass indexes, coronary flow reserve, ECV or aortic pulse wave velocity. Echocardiographic indices of LV diastolic function (E/e' and mitral E/A ratio) were not influenced. No safety concerns were identified.

Conclusions/interpretation: Empagliflozin had predicted effects on the dysglycaemia but did not influence variables expressing LV function, coronary flow reserve and ECV. An explanation may be that the LV function of the patients was within the normal range.

Keywords: Acute coronary syndrome; Cardiac magnetic resonance tomography; Dysglycaemia; Echocardiography; Empagliflozin; SGLT-2-inhibition.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Benzhydryl Compounds / pharmacology
  • Benzhydryl Compounds / therapeutic use
  • Diabetes Mellitus, Type 2* / complications
  • Female
  • Glucose / therapeutic use
  • Glucose Intolerance* / complications
  • Glucose Intolerance* / drug therapy
  • Humans
  • Male
  • Myocardial Infarction* / drug therapy
  • Pulse Wave Analysis
  • Sodium
  • Sodium-Glucose Transport Proteins / pharmacology
  • Ventricular Function, Left

Substances

  • empagliflozin
  • Glucose
  • Benzhydryl Compounds
  • Sodium-Glucose Transport Proteins
  • Sodium